PX1 Research supplies high-purity, synthetic tesamorelin acetate for analytical, in vitro, and preclinical research applications. Every lot undergoes rigorous third-party verification to confirm sequence identity, chemical purity, and low endotoxin levels prior to distribution.
PX1 Research supplies high-purity, synthetic tesamorelin acetate for analytical, in vitro, and preclinical research applications. Every lot undergoes rigorous third-party verification to confirm sequence identity, chemical purity, and low endotoxin levels prior to distribution.
To buy original tesamorelin acetate for non-clinical laboratory applications, qualified institutions must partner with certified chemical suppliers that provide comprehensive analytical transparency. Original tesamorelin acetate is a synthetic 44-amino acid growth-hormone-releasing hormone (GHRH) derivative stabilized by a trans-3-hexenoyl group. Verified reference standards require full analytical validation, including reverse-phase high-performance liquid chromatography (RP-HPLC) showing greater than 98% purity, electrospray ionization mass spectrometry (ESI-MS) confirming molecular mass, and chromogenic LAL assays validating minimal endotoxin levels.
PX1 Research provides fully documented, US-manufactured research peptides designed exclusively for controlled laboratory settings. Every batch of tesamorelin acetate is accompanied by a downloadable, lot-specific Certificate of Analysis (COA) issued by an independent ISO 17025 accredited laboratory, ensuring absolute batch-to-batch consistency and sequence fidelity for downstream experimental models.
Tesamorelin acetate (CAS 218949-48-5) is a stabilized synthetic analogue of human growth hormone-releasing factor (GRF 1-44). Its primary sequence consists of 44 amino acids terminated with a C-terminal amide group, structurally identical to natural endogenous GHRH. However, tesamorelin features a distinct N-terminal modification: a hexenoyl group attached to the tyrosine residue at position 1 (trans-3-hexenoyl-Tyr1-GHRH 1-44 amide). This chemical modification alters its enzymatic degradation kinetics relative to native native peptides available across our all peptides catalog.
The addition of the hydrophobic trans-3-hexenoyl moiety increases resistance to dipeptidyl peptidase-4 (DPP-4) cleavage in enzymatic models, substantially extending the peptide's half-life compared to unmodified native GHRH(1-44). In aqueous solution, the compound exhibits an isosbestic point under spectroscopic analysis and exists as an acetate salt formulation to optimize stability during lyophilization. Understanding these structural parameters is critical when calculating molar concentrations for in vitro binding assays or designing controlled administration protocols in rodent models.
At the cellular level, tesamorelin acetate functions as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR), a G-protein coupled receptor predominantly localized on somatotroph cells in the anterior pituitary gland. Upon ligand binding, the receptor undergoes a conformational shift that activates the stimulatory G-protein subunit (Gs alpha), driving the downstream activation of adenylyl cyclase. This enzyme converts adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP), triggering intracellular protein kinase A (PKA) signaling cascades.
Phosphorylation of transcriptional mediators via the PKA pathway stimulates both the transcription of the growth hormone (GH) gene and the influx of extracellular calcium through voltage-gated calcium channels. This dual mechanism induces pulsatile secretion of endogenous growth hormone into surrounding media or systemic circulation. Subsequently, circulating growth hormone targets hepatic and peripheral tissues, inducing gene expression of insulin-like growth factor 1 (IGF-1), which mediates downstream anabolic, metabolic, and cellular signaling networks under evaluation in preclinical research.
In animal models of metabolic dysfunction and diet-induced obesity, preclinical studies suggest that targeted GHRHR stimulation by tesamorelin acetate plays a pivotal role in modulating lipid kinetics. Growth hormone acts as a potent lipolytic agent by upregulation of hormone-sensitive lipase (HSL) and downregulating lipoprotein lipase (LPL) activity in adipocytes. Rodent models receiving controlled infusions of tesamorelin acetate demonstrate marked reductions in visceral adipose tissue (VAT) accumulation without significant perturbations to peripheral insulin sensitivity.
Furthermore, in vitro research utilizing primary hepatocytes indicates that GHRH signaling reduces hepatic triglyceride accumulation. By promoting mitochondrial beta-oxidation and modulating lipid export pathways, tesamorelin acetate helps researchers investigate pathways involved in non-alcoholic fatty liver disease (NAFLD) and hepatic steatosis. Laboratory investigations focus on quantifying transcript levels of carnitine palmitoyltransferase-1 (CPT-1) and sterol regulatory element-binding protein 1c (SREBP-1c) following peptide exposure.
Beyond metabolic pathways, growth hormone and IGF-1 axis upregulation is central to tissue regeneration models. In vitro assays using skeletal muscle myoblasts (such as C2C12 cell lines) demonstrate that treatment with tesamorelin acetate media accelerates myotube hypertrophy and increases total protein accretion. The underlying mechanism involves activation of the Akt/mTOR (mammalian target of rapamycin) cascade, which enhances translation initiation factors and ribosomal biogenesis.
In vivo rodent injury models highlight the impact of GHRH analog administration on extracellular matrix remodeling. Preclinical data indicate accelerated hydroxyproline turnover, increased Type I and Type III collagen deposition, and enhanced tensile strength recovery in tendinous and dermal wound models. Researchers frequently utilize tesamorelin acetate as a controlled reference standard to measure fibroblast proliferation, capillary density, and local cytokine modulation during early-stage repair phases.
When designing comparative secretagogue studies, researchers often evaluate tesamorelin acetate against other GHRH derivatives and growth hormone secretagogues (GHS). For instance, cjc-1295 no dac represents a truncated 29-amino acid GHRH analog (tetrasubstituted GRF 1-29) designed for short-acting receptor stimulation, whereas sermorelin retains the native sequence of the first 29 amino acids of human GHRH. In contrast, tesamorelin acetate maintains the full 44-amino acid length with an added lipophilic tail, altering its receptor binding kinetics and enzymatic stability relative to shorter fragments.
Additionally, while GHRH analogs target the GHRHR directly, ghrelin receptor agonists like ghrp-6 or ipamorelin stimulate growth hormone release through an entirely distinct pathway: the growth hormone secretagogue receptor (GHSR-1a). Dual-pathway studies frequently pair a GHRH agonist like tesamorelin with a GHSR agonist to evaluate synergistic intracellular cAMP and calcium mobilization in somatotroph cell cultures.
To ensure reproducible experimental outcomes, laboratories must avoid unverified, low-purity crude peptides. Purchasing authentic tesamorelin acetate requires verification through multi-spectral analytical testing. A legitimate analytical dossier must include reverse-phase high-performance liquid chromatography (RP-HPLC) chromatograms demonstrating a main peak area purity of 98% or higher, eliminating concerns regarding truncated peptide fragments or deletion sequences.
Identity confirmation requires electrospray ionization mass spectrometry (ESI-MS) to verify the precise monoisotopic mass of the hexenoyl-GHRH conjugate (molecular weight ~5136.9 Da). Furthermore, because bacterial endotoxins (lipopolysaccharides) can confound cellular assays and animal immune responses, quality-focused suppliers perform quantitative LAL (Limulus Amebocyte Lysate) testing to ensure endotoxin levels remain strictly under 0.01 EU/mg.
Tesamorelin acetate is supplied as a sterile, lyophilized white powder to maximize shelf-life stability during storage and transport. For laboratory reconstitution, technicians should allow the vial to equilibrate to room temperature before adding diluents to prevent condensation shock. The standard diluent for short-term in vitro assays is sterile target-grade water or phosphate-buffered saline (PBS, pH 7.4). For multi-dose animal studies requiring extended stability under refrigeration, sterile 0.9% bacteriostatic sodium chloride containing 0.9% benzyl alcohol is recommended.
When adding diluent, liquid should be directed down the glass wall of the vial rather than sprayed directly onto the lyophilized cake to prevent shear stress and peptide denaturation. Gently swirl the vial until complete dissolution occurs; never vortex reconstituted peptide solutions. Reconstituted aliquots should be divided into single-use volumes to eliminate repeated freeze-thaw cycles, which accelerate peptide aggregation and chemical cleavage of the peptide backbone.
Lyophilized tesamorelin acetate maintains optimal chemical integrity when stored at -20°C in a manual defrost freezer, shielded from direct light exposure. Under these conditions, the desiccated peptide cake remains stable for up to 24 months. For long-term preservation exceeding two years, storage at -80°C is recommended to minimize spontaneous hydrolysis or oxidation of sensitive methionine and tryptophan residues.
Once reconstituted into solution, tesamorelin acetate exhibits reduced chemical stability. Aqueous solutions maintained at 2°C to 8°C should be utilized within 14 to 21 days depending on the choice of preservative. Exposure to elevated temperatures, ambient room light, or basic pH environments (>8.0) accelerates degradation pathways such as deamidation at asparagine residues. Institutional laboratories requiring steady experimental supply can establish standing orders through PX1's wholesale program to ensure continuous access to freshly synthesized lots.
PX1 Research operates strictly as a specialized domestic supplier of analytical-grade research chemicals. All peptides featured in our catalog are synthesized inside US-based laboratories operating under cGMP-compliant standards and ISO 9001 quality management systems. By maintaining local synthesis and analytical infrastructure, PX1 eliminates the quality variations, customs delays, and contamination risks associated with unverified overseas distributors.
Every batch of tesamorelin acetate shipped from our California and Arizona fulfillment centers includes full lot traceability and direct access to third-party ISO 17025 verification documents. Orders placed Monday through Friday ship same-day, arriving in temperature-controlled packaging engineered to preserve peptide structure throughout transit. Researchers can explore our complete GHRH analog research library for comprehensive structural data and reference literature.
What is the purity specification of PX1 Research tesamorelin acetate?
PX1 Research guarantees that all lots of tesamorelin acetate achieve >98% chemical purity as determined by Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) analysis.
How is the identity of original tesamorelin acetate verified?
Identity is confirmed using Electrospray Ionization Mass Spectrometry (ESI-MS), which verifies the exact molecular weight and structural sequence of the hexenoyl-modified 44-amino acid chain.
Is tesamorelin acetate approved for human administration or therapeutic use?
No. Tesamorelin acetate supplied by PX1 Research is sold strictly for in vitro, analytical, and preclinical laboratory research applications. It is not intended for human or animal therapeutic use, clinical administration, or diagnostic procedures.
What are the recommended storage conditions for lyophilized tesamorelin acetate?
Lyophilized tesamorelin acetate should be stored at -20°C or -80°C in a dry, dark environment. Reconstituted solutions must be kept refrigerated at 2°C to 8°C and used within specified laboratory timeframes.
What endotoxin thresholds are tested on PX1 Research peptides?
Every lot undergoes quantitative Chromogenic LAL testing to verify endotoxin levels are maintained below 0.01 EU/mg, preventing endotoxin interference in sensitive cellular or animal models.
What is the difference between tesamorelin and sermorelin in research applications?
Tesamorelin is a full-length 44-amino acid GHRH derivative stabilized by an N-terminal trans-3-hexenoyl group, whereas sermorelin is a 29-amino acid fragment (GRF 1-29). The hexenoyl group in tesamorelin enhances resistance to DPP-4 enzymatic degradation.
What diluent should be used for reconstituting tesamorelin acetate in the lab?
For acute in vitro experiments, sterile water or PBS is typically utilized. For multi-dose animal studies requiring extended refrigerated stability, sterile 0.9% bacteriostatic water (containing benzyl alcohol) is standard.
How fast are research orders fulfilled and shipped by PX1 Research?
Orders placed Monday through Friday before cut-off times ship same-day from our dual fulfillment centers located in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.